greeksoup/ stock research

Elanco Animal Health (ELAN) Q2 FY2023 earnings: revenue $1.1 billion, down 10.2% on the year

Elanco Animal Health Inc. (ELAN) reported revenue of $1.1 billion for Q2 FY2023, the quarter ended 30 June 2023, down 10.2% on the same quarter a year earlier. Net income was -$97 million, and diluted earnings per share $-0.20. The figures are the company's own, from the 10-Q it filed with the SEC on 7 August 2023.

Revenue
$1.1 billion
-10.2% on the year · -15.9% on the quarter
Q3 FY2021Q2 FY2023
Operating margin
-7.5%
-1.0% a year earlier
Q3 FY2021Q2 FY2023
Net income
-$97 million
Q3 FY2021Q2 FY2023
Diluted EPS
-$0.20
Q3 FY2021Q2 FY2023

this quarterthe same quarter a year earlierHover a bar for its figure.

Income statement (profit and loss)

$ millionQ2 FY2023Q1 FY2023Q2 FY2022On the quarterOn the yearLast 8 quarters
Revenue1,0571,2571,177-15.9%-10.2%
Cost of revenue434494484-12.1%-10.3%
Gross profit623763693-18.3%-10.1%
Gross margin58.9%60.7%58.9%
Research and development81.081.082.00.0%-1.2%
Selling, general and administrative353327343+8.0%+2.9%
Operating income-79.0108-12.0
Operating margin-7.5%8.6%-1.0%
Interest expense74.064.067.0+15.6%+10.4%
Pre-tax income-79.0108-14.0
Income tax18.05.0-4.0+260.0%
Effective tax raten/a4.6%n/a
Net income-97.0103-10.0
Net margin-9.2%8.2%-0.8%
Diluted EPS-$0.20$0.21-$0.02
$ million except per share.
Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed.

Cash flow

$ millionQ2 FY2023Q1 FY2023Q2 FY2022On the quarterOn the yearLast 8 quarters
Operating cash flow61.0-145312-80.4%
Capital expenditure46.020.026.0+130.0%+76.9%
Free cash flow15.0-165286-94.8%
Free cash flow margin1.4%-13.1%24.3%
Cash from investing-43.0-55.0-37.0
Cash from financing39.0174-96.0-77.6%
Depreciation and amortisation177173171+2.3%+3.5%
Share-based compensation9.012.017.0-25.0%-47.1%
Diluted shares, weighted493m493m488m-0.0%+0.9%
Shares outstanding at period end493m492m474m+0.0%+3.9%

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet

$ millionQ2 FY2023Q1 FY2023Q2 FY2022On the quarterOn the yearLast 8 quarters
Shareholders' equity7,4207,4807,140-0.8%+3.9%
Debt6,0626,0206,063+0.7%-0.0%
Other liabilities2,3142,2692,398+2.0%-3.5%
Total liabilities and equity15,79615,76915,601+0.2%+1.2%
Fixed assets1,0071,000961+0.7%+4.8%
Goodwill6,0406,0615,898-0.3%+2.4%
Intangible assets4,6784,7915,059-2.4%-7.5%
Cash and equivalents367318507+15.4%-27.6%
Receivables1,0001,051916-4.9%+9.2%
Inventory1,6901,5961,334+5.9%+26.7%
Other assets1,014952926+6.5%+9.5%
Total assets15,79615,76915,601+0.2%+1.2%

Questions

What was Elanco Animal Health's revenue in Q2 FY2023?

Elanco Animal Health (ELAN) reported revenue of $1.1 billion for Q2 FY2023, the quarter ended 30 June 2023, down 10.2% on the same quarter a year earlier.

How much did Elanco Animal Health earn in Q2 FY2023?

Net loss for Q2 FY2023 was $97 million, and the diluted loss per share $0.20.

When did Elanco Animal Health report Q2 FY2023 results?

Elanco Animal Health filed its 10-Q for the quarter ended 30 June 2023 with the SEC on 7 August 2023.

Quarterly results, the last 20 quarters

Q4 FY2021Q1 FY2022 †Q2 FY2022 †Q3 FY2022 †Q4 FY2022 * †Q1 FY2023Q2 FY2023Q3 FY2023Q4 FY2023 *Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024 *Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025 *Q1 FY2026Q2 FY2026Q3 FY2026
Revenue1,1121,2251,1771,0289811,2571,0571,0681,0351,2051,1841,0301,0201,1931,2411,1371,1441,3711,3681,265
Cost of revenue512509484472448494434487516515495492501509528530555586570545
Gross profit600716693556533763623581519690689538519684713607589785798720
Gross margin54%58%59%54%54%61%59%54%50%57%58%52%51%57%57%53%51%57%58%57%
R&D92.081.082.078.080.081.081.086.079.087.089.087.081.094.092.089.093.097.092.099.0
SG&A327323343298301327353313292337354323300341400351338381449393
Operating income-12274.0-12.0-42.0-92.0108-79.0-1,097-12712.0-32.0559-51.0n/an/an/an/an/an/an/a
Operating margin-11%6%-1%-4%-9%9%-7%-103%-12%1%-3%54%-5%n/an/an/an/an/an/an/a
Interest expense55.052.067.060.062.064.074.072.067.066.065.058.0n/an/an/an/an/an/an/an/a
Pre-tax income-12075.0-14.0-44.0-89.0108-79.0-1,097-12712.0-32.0559-51.060.025.0-50.0-25987.056.024.0
Tax raten/a32%n/an/an/a5%n/an/an/a-167%n/a35%n/a-12%56%n/an/a34%4%25%
Net income-10551.0-10.0-65.0-54.0103-97.0-1,096-14132.0-50.0364-8.067.011.0-34.0-27657.054.018.0
Net margin-9%4%-1%-6%-6%8%-9%-103%-14%3%-4%35%-1%6%1%-3%-24%4%4%1%
Diluted EPS-$0.22$0.10-$0.02-$0.13-$0.11$0.21-$0.20-$2.22-$0.29$0.06-$0.10$0.73-$0.02$0.13$0.02-$0.07-$0.56$0.11$0.11$0.04
Operating cash flow223-62.031218913.0-14561.01981572.0200162177-4.023721910813.0277216
Capital expenditure66.019.026.026.066.020.046.033.041.024.034.042.047.065.057.092.062.051.033.060.0
Free cash flow157-81.0286163-53.0-16515.0165116-22.0166120130-69.018012746.0-38.0244156
Shares outstanding473m474m474m474m474m492m493m493m493m494m494m494m494m496m497m497m497m499m500m500m
Filing10-K10-K10-K10-K10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q
Each quarter as filed, linked to its filing.
Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

10-Q for the period ended 30 June 2023, filed 7 August 2023: the filing.